NICOX SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.373 EUR | -0.67% |
|
-1.06% | -13.56% |
| 22/04 | Nicox: cash position of 9.1 million euros at the end of March | CF |
| 28/02 | Nicox, BlackRock Sign Deal for Debt Restructuring | MT |
| Sales 2023 | 4.2M 4.49M 375M | Sales 2024 * | 9.2M 9.84M 820M | Capitalization | 18.7M 20M 1.67B |
|---|---|---|---|---|---|
| Net income 2023 * | -15M -16.04M -1.34B | Net income 2024 * | -14M -14.97M -1.25B | EV / Sales 2023 | 5.25 x |
| Net Debt 2023 * | 9.24M 9.88M 824M | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 2.03 x |
| P/E ratio 2023 * |
-1.25
x | P/E ratio 2024 * |
-1.56
x | Employees | - |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 93.38% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 week | -1.06% | ||
| Current month | -4.73% | ||
| 1 month | -4.97% | ||
| 3 months | -10.01% | ||
| 6 months | +12.86% | ||
| Current year | -13.56% |
1 week
0.37
0.38
1 month
0.370.39
3 years
0.314.31
| Managers | Title | Age | Since |
|---|---|---|---|
Gavin M. Spencer
CEO | Chief Executive Officer | 53 | 01/05/01 |
Michele Garufi
FOU | Founder | 70 | 15/96/15 |
Sandrine Gestin
DFI | Director of Finance/CFO | 56 | 01/99/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Les Kaplan
BRD | Director/Board Member | 73 | 01/14/01 |
| Director/Board Member | 65 | 18/17/18 | |
Adrienne Graves
BRD | Director/Board Member | 69 | 08/14/08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.373 | -0.67% | 0 |
| 25/24/25 | 0.3755 | 0.00% | 0 |
| 24/24/24 | 0.3755 | +0.13% | 0 |
| 23/24/23 | 0.375 | +0.27% | 0 |
| 22/24/22 | 0.374 | -0.80% | 0 |
Real-time BOERSE MUENCHEN, April 27, 2024 at 01:13 am IST
More quotes
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The Company is also conducting research on NCX 1728 in retinal conditions. NCX 4251 for topical ocular application for dry eye disease is being developed by Nicox's licensed partner Ocumension Therapeutics in China and is available for partnering elsewhere. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow Health, Inc. in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets."
Sector
Pharmaceuticals
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.374
EUR
Average target price
1
EUR
Spread / Average Target
+167.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- ALCOX Stock
- NXOA Stock
